If approved, Luye Pharma's schizophrenia drug LY03010 faces a crowded market
China-based Luye Pharma’s (SEHK: 2186) pipeline asset LY03010, a once-monthly, long-acting injectable (LAI) form of paliperidone, has achieved the primary endpoint in a pivotal trial and demonstrated comparable bioavailability with Johnson & Johnson’s (NYSE: JNJ) Invega Sustenna (1-month paliperidone palmitate) at steady state.
If approved, it will create more options for the management of schizophrenia, but will have to face a crowded LAI market, says data and analytics company GlobalData.
According to GlobalData’s report, “ Schizophrenia Market Size and Trend Report including Epidemiology and Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031,” LY03010 is anticipated to be launched in the USA in second-quarter 2024. It is forecast to reach sales of $63.5 million in 2031, representing 0.6% of the US schizophrenia market in 2031.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze